Back

Implantable cardioverter-defibrillator therapy compared to amiodarone in Chagas cardiomyopathy: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Hot topics in device therapy Device Treatment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Melissa Chacon Quiros

Hospital Internacional La Católica, San Jose (Costa Rica)

6 More presentations in this session

Presentation thumbnail
Real-world radiotherapy and healthcare utilization in patients implanted with cardiac implantable electronic devices
Mr L. Higuera (Mounds View, US)
Abstract Slides Video
Presentation thumbnail
ICD therapy in patients with preserved LVEF and monomorphic VT
Doctor S. Vakilzadeh-Hashemi (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Comparison of long-term outcomes between left bundle branch-optimized cardiac resynchronization therapy and conventional biventricular pacing in cardiac resynchronization therapy upgrades
Doctor K. Misonou (Kitakyushu, JP)
Abstract Slides Video
Presentation thumbnail
Clinical impact of late phase responder in cardiac resynchronization therapy
Doctor Y. Kitami (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Cardiac resynchronization therapy and clinical outcomes in patients with advanced left ventricular dysfunction and a wide QRS
Doctor G. Golovchiner (Petah Tikva, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Hot topics in device therapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Clinical outcomes after implantable cardioverter-defibrillator therapy in patients with chronic Chagas cardiomyopathy: an updated systematic review and meta-analysis
thumbnail
Congress Presentation
Wearable cardioverter-defibrillator compared to beta blockers in patients at risk of sudden death: a real-world propensity score-matched study.
thumbnail
Congress Session
Late-Breaking Clinical Trials: recent advances in CIED therapies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources